
|Videos|January 11, 2023
2022 Society of Urologic Cancer Annual Meeting recap - SUO/YUO research highlight
Author(s)Urology Times staff
“The takeaway from that talk was that it's critically important to review drug plan options, particularly if the patient's on a high-cost drug,” says Kelly L. Stratton, MD, FACS.
Advertisement
In this video, Kelly L. Stratton, MD, FACS, recaps a presentation from the 2022 Society of Urologic Oncology Annual Meeting Young Urologic Oncologists Program regarding cost savings for prostate cancer treatments. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5













